Development of a Cascade of Care for responding to the opioid epidemic

References

• Centers for Disease Control and Prevention. National Vital Statistics System. Provisional counts of drug overdose deaths as of 9/5/2018. Centers for Disease Control and Prevention: National Center for Health Statistics; 2018.
   Google Scholar
• Williams AR, Bisaga A. From AIDS to opioids - how to respond to an epidemic. N Engl J Med. 2016 Sept 1;375(9):813–15. doi:10.1056/NEJMp1604223.
   PubMed Web of Science ®Google Scholar
• Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. HIV/AIDS. 2011;52(6):793–800.
   Google Scholar
• Ali MK, Bullard KM, Gregg EW, del Rio C. A Cascade of Care for diabetes in the United States: visualizing the gaps. Ann Intern Med. 2014;161(10):681–89. doi:10.7326/M14-0019.
   PubMed Web of Science ®Google Scholar
• Yehia BR, Schranz A, Umscheid CA, Lo Re V, Rizza SA. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS ONE. 2014;9(7):e 101554. doi:10.1371/journal.pone.0101554.
   Web of Science ®Google Scholar
• Horn T, Sherwood J, Remien RH, Nash D, Auerbach JD. Towards an integrated primary and secondary HIV prevention continuum for the United States: a cyclical process model. J Int AIDS Soc.2017 November 19; 21263.
   Web of Science ®Google Scholar
• Gonsalves GS, Paltiel AD, Cleary PD, Gill MJ, Kitahata MM, Rebeiro PF, Silverberg MJ, Horberg M, Abraham AG, Althoff KN, et al. A flow-based model of the HIV care continuum in the United States. J Acquir Immune Defic Syndr. 2017;75(5):548–53. doi:10.1097/QAI.0000000000001429.
   PubMed Web of Science ®Google Scholar
• Williams AR, Nunes EV, Olfson M. To battle the opioid overdose epidemic, deploy the “Cascade of Care” model. Health Affairs Blog. March 13 2017. [accessed 2018 Nov 13]. https://www.healthaffairs.org/do/10.1377/hblog20170313.059163/full/
   Google Scholar
• Socias EM, Volkow N, Wood E. Adopting the ‘Cascade of Care’ framework: an opportunity to close the implementation gap in addiction care? Addiction. 2016. doi:10.1111/add.13479.
   PubMed Web of Science ®Google Scholar
• SAMHSA Substance Abuse and Mental Health Services Administration. Results from the 2016 National Survey on Drug Use and Health. Rockville, MD: HHS. SMA17-5044; 2017.
   Google Scholar
• Compton WM, Dawson D, Duffy SQ, Grant B. The effect of inmate populations on estimates of DSM-IV alcohol and drug use disorders in the United States. Am J Psychiatry. 2009;167(4):473–74. doi:10.1176/appi.ajp.2009.09081087.
   Web of Science ®Google Scholar
• Williams AR. Performance measures and quality improvement for the opioid epidemic. In: Compton M, Manseau MW, editors. Opioid addiction: an American crisis. Arlington, VA: APPI Press; 2018.
   Google Scholar
• Cicero TJ, Ellis MS. Understanding the demand side of the prescription opioid epidemic: does the initial source of opioids matter? Drug Alcohol Depend. 2017;173:S4–S10. doi:10.1016/j.drugalcdep.2016.03.014.
   PubMed Web of Science ®Google Scholar
• Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–63. doi:10.1056/NEJMra1508490.
   PubMed Web of Science ®Google Scholar
• Babor T, McRee B, Kassebaum P, Grimaldi PL, Ahmed K, Bray J. Screening, Brief Intervention, and Referral to Treatment (SBIRT). Subst Abuse. 2017;28(3):7–30. doi:10.1300/J465v28n03_03.
   Google Scholar
• Abdul-Quader AS, Feelemeyer J, Modi S, Stein ES, Briceno A, Semaan S, Horvath T, Kennedy GE, des Jarlais DC. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review. AIDS Behav. 2013;17(9):2878–92. doi:10.1007/s10461-013-0593-y.
   PubMed Web of Science ®Google Scholar
• Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, Bohm MK, Jones CM, Flanagan BE, Siddiqi A-E-A, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):323–31. doi:10.1097/QAI.0000000000001098.
   PubMed Web of Science ®Google Scholar
• D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized controlled trial. JAMA. 2015;313(16):1636–44. 28 doi:10.1001/jama.2015.3474.
   PubMed Web of Science ®Google Scholar
• Winkelman TNA, Chang VW, Binswanger I. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558. doi:10.1001/jamanetworkopen.2018.0558.
   PubMed Web of Science ®Google Scholar
• Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM, Hardin C, Rosenblum A, Dora M, Hardin C, Marlowe D, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44:473–80.
   PubMed Web of Science ®Google Scholar
• National Association of Drug Court Professionals. Adult drug court best practice standards. Vol. ume II Alexandria VA: NADCP; 2015.
   Google Scholar
• Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren J. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2010;106:32–51. doi:10.1111/j.1360-0443.2010.03140.x.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550:1–14.
   PubMed Web of Science ®Google Scholar
• Samples H, Williams AR, Olfson M, Crystal S. Risk factors for premature discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9–17. doi:10.1016/j.jsat.2018.09.001.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Wei-Hsuan LC, Cochran G, Gellad WF, Cathers T, Kelley D, Donohue JM. Patterns and quality of buprenorphine opioid agonist treatment in a large Medicaid program. J Addict Med. 2015;9(6):470–77. doi:10.1097/ADM.0000000000000164.
   PubMed Web of Science ®Google Scholar
• Stein B, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–12. doi:10.1001/jama.2016.10542.
   PubMed Web of Science ®Google Scholar
• Jarvis B, Holtyn A, Subramanian S, Tompkins DA, Oga EA, Bigelow GE, Silverman K. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. in Press. 2018. doi:10.1111/add.14180.
   Web of Science ®Google Scholar
• Morgan JR, Shackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine/naloxone utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2017 Jul 3. doi:10.1016/j.jsat.2017.07.001. pii: S0740-5472(16)30413-15. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–67. doi:10.1097/ADM.0000000000000166.
   PubMed Web of Science ®Google Scholar
• National Quality Forum (NQF). (2017). Behavioral health 2016–2017: technical report. Department of Health and Human Services. https://www.qualityforum.org/Publications/2017/08/Behavioral_Health_2016-2017_Final_Report.aspx
   Google Scholar
• Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorders – Exhibit 2.16. 2018, 2–24. accessed 2018 October 1. https://store.samhsa.gov/product/SMA18-5063FULLDOC.
   Google Scholar
• The ASAM. ASAM performance measures for the addiction specialist physician. Chevy Chase, MD: The American Society for Addiction Medicine; 2014.
   Google Scholar
• National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA. 1998;280(22):1936–43.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva, Switzerland: WHO Management of Substance Abuse Team; 2009.
   Google Scholar
• Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, Remien RH, Crystal S, Friedmann PD, Levin FR, et al. Developing an opioid use disorder treatment cascade: a review of quality measures. J Subst Abuse Treat. 2018;91:57–68. doi:10.1016/j.jsat.2018.06.001.
   PubMed Web of Science ®Google Scholar
• Lee JD, Rotrosen J, Nunes EV, Tanum L (2018). Effectiveness of XR-Naltrexone vs. Buprenorphine: Results of Two Randomized Trials. ASAM National Conference, San Diego, April 12–15, 2018.
   Google Scholar
• Sigmon SC, Meyer A, Hruska B, Ochalek T, Rose G, Badger GJ, Brooklyn JR, Heil SH, Higgins ST, Moore BA, et al. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility. Addict Behav. 2015 Dec;51:136–42. doi:10.1016/j.addbeh.2015.07.030. Epub 2015 Jul 29.
   PubMed Web of Science ®Google Scholar
• Goldman ML, Spaeth-Rublee B, Nowels AD, Ramanuj PP, Pincus HA. Quality measures at the interface of behavioral health and primary care. Curr Psychiatry Rep. 2016;18(39):1–8. doi:10.1007/s11920-015-0646-1.
   PubMed Web of Science ®Google Scholar
• Pincus HA, Scholle SH, Spaeth-Rublee B, Hepner KA, Brown J. Quality measures for mental health and substance use: gaps, opportunities, and challenges. Health Aff. 2016;35(6):1000–08. doi:10.1377/hlthaff.2016.0027.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Gordon M, Friedmann P, Fishman MJ, Lee JD, Chen DT, Hu MC, Boney TY, Wilson D, O’Brien CP. Relapse to opioid use disorder after inpatient treatment: protective effect of injection naltrexone. J Subst Abuse Treat. 2018;Feb(85:49–55. doi:10.1016/j.jsat.2017.04.016.
   Web of Science ®Google Scholar
• Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S, Gossop M. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ. 2003;326:959–60. doi:10.1136/bmj.326.7396.959.
   PubMed Web of Science ®Google Scholar
• Volkow N, Woodcock J, Compton WM, Cui Q, Kachko A, Cotler SJ, Hajarizadeh B, Sacks-Davis R, Page K, Boodram B, et al. Medication development in opioid addiction: meaningful clinical end points. Sci Transl Med. 2018;10:eaan2595. doi:10.1126/scitranslmed.aao4496.
   PubMed Web of Science ®Google Scholar
• Williams AR. After many years, the FDA announces loosened standards for addiction medication approval. Health Affairs Blog. 2018;23:2018.
   Google Scholar
• Dennis ML, Scott CK. Four-year outcomes from the Early Re-Intervention (ERI) experiment using Recovery Management Checkups (RMCs). Drug Alcohol Depend. 2012 Feb 1;121(1–2):10–17. doi:10.1016/j.drugalcdep.2011.07.026.
   PubMed Web of Science ®Google Scholar
• Tai B, Volkow ND. Treatment for substance use disorder: opportunities and challenges under the affordable care act. Soc Work Public Health. 2013;28(3–4):165–74. doi:10.1080/19371918.2013.758975.
   PubMed Web of Science ®Google Scholar
• Horberg MA, Hurley LB, Klein DB, Towner WJ, Kadlecik P, Antoniskis D, Mogyoros M, Brachman PS, Remmers CL, Gambatese RC, et al. The HIV Care Cascade measured over time and by age, sex, and race in large national integrated care system. AIDS Patient Care STDS. 2015;29(11):582–90. doi:10.1089/apc.2015.0139.
   PubMed Web of Science ®Google Scholar
• Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57(8):1164–71. doi:10.1093/cid/cit420.
   PubMed Web of Science ®Google Scholar
• Zanoni BC, Mayer KH, Adolescent T. Young adult HIV Cascade of Care in the United States: exaggerated health disparities. AIDS Patient Care STDS. 2013;28(3):128–35. doi:10.1089/apc.2013.0345.
   Web of Science ®Google Scholar
• Belenko S, Knight D, Wasserman GA, Dennis ML, Wiley T, Taxman FS, Oser C, Dembo R, Robertson AA, Sales J. The juvenile justice behavioral health services cascade: a new framework for measuring unmet substance use treatment services needs among adolescent offenders. J Subst Abuse Treat. 2017;74:80–91. doi:10.1016/j.jsat.2016.12.012.
   PubMed Web of Science ®Google Scholar
• Pescosodio BA, Martin JK, Long JS, Medine TR, Phelan JC, Link BG. “A disease like any other”? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence. Am J Psychiatry. 2010;167(11):1321–30. doi:10.1176/appi.ajp.2010.09121743.
   PubMed Web of Science ®Google Scholar
• Barry CL, McGinty EE, Pescosodio B, Hh G. Stigma, discrimination, treatment effectiveness and policy support: comparing public views about drug addiction with mental illness. Psychiatr Serv. 2014;65(10):1269–72. doi:10.1176/appi.ps.201400140.
   PubMed Web of Science ®Google Scholar
• Grogan CM, Andrews C, Abraham A, Humphreys K, Pollack HA, Smith BT, Friedmann PD. Survey highlights differences in Medicaid coverage for substance use treatment and opioid use disorder medications. Health Aff (Millwood). 2016;35(12):2289–96. doi:10.1377/hlthaff.2016.0623.
   PubMed Web of Science ®Google Scholar
• Chalk M, Mark T. Deploying the Cascade of Care framework to address the opioid epidemic means taking a closer look at quality measures. Health Affairs, Health Policy Lab. June 21 2017. [accessed 2018 Nov 13]. https://www.healthaffairs.org/do/10.1377/hblog20170621.060677/full/
   Google Scholar
• Barrett J, Li M, Spaeth-Rublee B, Pincus HA. Value-based payment as part of a broader strategy to address opioid addiction crisis. Health Affairs blog. December 1 2017. [accessed 2018 Nov 13]. https://www.healthaffairs.org/do/10.1377/hblog20171130.772229/full/
   Google Scholar
• Saloner B. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004–2013 during the last decade, nonmedical use. JAMA. 2015;314(14):1515–17. doi:10.1001/jama.2015.10345.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117–27. doi:10.1016/j.drugalcdep.2016.10.015.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Friedan TR, Hyde PS, Cha SS. Medication-assisted therapies- tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–66. doi:10.1056/NEJMp1402780.
   PubMed Web of Science ®Google Scholar
• SAMHSA Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2015. Data on substance abuse treatment facilities. BHSIS series S-88, HHS Publication No. (SMA) 17-5031. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017.
   Google Scholar
• Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016; 35(1):22–35. doi:10.1080/10550887.2016.1100960.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018. doi:10.7326/M17-3107.
   PubMed Web of Science ®Google Scholar
• Green TC, Clarke J, Brinkley-Rubenstein L, Garavan H, Childress AR, Paulus MP, Volkow ND. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405–07. doi:10.1001/jamapsychiatry.2017.4614.
   PubMed Web of Science ®Google Scholar
• Goldstein RZ, Craig AD, Bechara A, Garavan H, Childress AR, Paulus MP, Volkow ND. The neurocircuitry of impaired insight in drug addiction. Trends Cogn Sci. 2009;13(9):372–80. doi:10.1016/j.tics.2009.06.004.
   PubMed Web of Science ®Google Scholar
• Williams AR, Olfson M, Galanter M. Assessing and improving clinical insight among patients in denial. JAMA Psychiatry. 2015;72(4):303–04. doi:10.1001/jamapsychiatry.2014.2684.
   PubMed Web of Science ®Google Scholar
• Capoccia VA, Grazier KL, Toal C, Ford JH, Gustafson DH. Massachusetts’s experience suggests coverage alone is insufficient to increase addiction disorders treatment. Health Aff. 2012;31(5):1000–08. doi:10.1377/hlthaff.2011.0326.
   Web of Science ®Google Scholar